Skip to main content
DIRUI INDUSTRIAL CO.,LTD. logo

DIRUI INDUSTRIAL CO.,LTD. — Investor Relations & Filings

Ticker · 300396 ISIN · CNE100001XS7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,689 across all filing types
Latest filing 2020-08-12 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300396

About DIRUI INDUSTRIAL CO.,LTD.

https://www.dirui.com.cn

DIRUI INDUSTRIAL CO.,LTD. specializes in the research, development, manufacturing, and distribution of medical laboratory instruments and diagnostic reagents. The company provides comprehensive solutions for in-vitro diagnostics (IVD), focusing on several key clinical areas including urinalysis, biochemistry, hematology, and chemiluminescence immunoassay. Its product portfolio features high-throughput automated analyzers and integrated laboratory systems designed to enhance diagnostic efficiency and accuracy. DIRUI serves a global market, providing medical institutions and laboratories with a wide range of diagnostic tools, from urine sediment analysis to vaginal secretion testing. The company emphasizes technological innovation and quality control to support clinical decision-making and patient care through reliable laboratory automation and standardized testing protocols.

Recent filings

Filing Released Lang Actions
关于对深圳证券交易所《关于对迪瑞医疗科技股份有限公司的问询函》相关问题的回复
Regulatory Filings Classification · 95% confidence The document is a detailed written reply from a company (迪瑞医疗科技股份有限公司) to an inquiry letter from the Shenzhen Stock Exchange regarding a specific transaction involving the transfer of an 11% equity stake in a subsidiary (宁波瑞源生物科技有限公司). The content includes detailed explanations about dividend distributions, financial impacts, strategic rationale for the equity transfer, performance targets, goodwill impairment testing, and corporate governance procedures related to the transaction. It is a regulatory response to an inquiry letter, focusing on clarifications and disclosures about a specific capital transaction and related financial and governance matters. The document does not contain a full annual or interim financial report, earnings release, or audit report. It is not a simple announcement but a detailed regulatory reply to a formal inquiry. This type of document fits best under Regulatory Filings (RNS), which covers general regulatory announcements, compliance documents, and responses to regulatory inquiries that do not fit other specific categories.
2020-08-12 Chinese
关于实际控制人部分股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the release of pledged shares by the company's actual controller. It details the number of shares released from pledge, the shareholder involved, and the status of pledged and frozen shares. There is no financial data, no report or presentation attached, and the document is short (1101 characters). It is a regulatory announcement about share pledge status, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like shareholding notifications (MRQ) which typically involve threshold crossings, or share issue/capital change (SHA).
2020-08-07 Chinese
关于获得发明专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company about receiving an invention patent certificate. It contains no financial data, no mention of financial results, no regulatory filings related to financial performance, and no meeting or voting information. It is a corporate announcement about intellectual property rights, which does not fit into any specific financial report category. Given the short length (628 characters) and the nature of the content, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous corporate announcements that do not fit other categories.
2020-08-06 Chinese
关于对深圳证券交易所《关于对迪瑞医疗科技股份有限公司的问询函》相关问题的回复
Regulatory Filings Classification · 95% confidence The document is a detailed written reply from a company (迪瑞医疗科技股份有限公司) to an inquiry letter from the Shenzhen Stock Exchange regarding a specific transaction involving the transfer of equity in a subsidiary (宁波瑞源生物科技有限公司). The content includes detailed explanations about valuation differences, goodwill impairment considerations, transaction purpose, impact on company operations, and financial effects. It references a 2020 half-year report and discusses financial data and strategic decisions related to the equity transfer. The document is not a full financial report like an annual or interim report, nor is it a simple announcement or certification. It is a regulatory response to an inquiry letter, providing clarifications and supplementary information about a specific transaction and its financial and operational implications. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories. The document length (8563 characters) and detailed content support this classification rather than a brief announcement or a full report.
2020-08-04 Chinese
拟股权转让所涉及的宁波瑞源生物科技有限公司股东全部权益价值项目资产评估说明
Audit Report / Information Classification · 95% confidence The document is a detailed asset valuation report prepared by an asset appraisal company (北京华亚正信资产评估有限公司) for the purpose of a proposed equity transfer involving 宁波瑞源生物科技有限公司, a subsidiary or related company of 迪瑞医疗科技股份有限公司. The report includes extensive financial data such as asset and liability details, profit and loss statements, asset verification procedures, and valuation methodologies (asset-based and income-based approaches). It is clearly an asset appraisal report related to a capital transaction (equity transfer). The document is not an annual or interim financial report, nor is it a regulatory filing or announcement. It is a standalone audit/valuation report focusing on asset valuation for a specific transaction. Therefore, the most appropriate classification is Audit Report / Information (AR). The document length (15,000 characters) and content confirm it is the full report, not just an announcement or certification. H1 2020
2020-07-30 Chinese
第四届董事会第九次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting, including approval of a related party transaction and the decision to convene a shareholders' meeting. It details voting results and procedural compliance but does not contain financial statements or detailed financial data. The content focuses on board decisions and management actions rather than financial reporting or shareholder voting results. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, nor is it a voting result declaration from a shareholder meeting. Hence, the classification is MANG with high confidence.
2020-07-30 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.